Sinquan

Quick links to important sections

Sinquan

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinquan

Quick Facts

Property Description
Active ingredient Doxepin hydrochloride
Form Oral Capsule, Oral Tablet, Oral Concentrate, Topical Cream
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Mood stabilization, anxiety relief, sleep aid
Origin Synthetic, Dibenzoxepin derivative

What is Sinquan and What is its Active Ingredient?

Sinquan is the trade name for a prescription-only medication containing the active ingredient doxepin hydrochloride. This synthetic drug is classified as a dibenzoxepin tricyclic compound and is supplied in multiple preparations, including oral capsules, tablets, oral concentrate solution, and a topical cream. Doxepin is a single-active ingredient product that exists as an isomeric mixture, containing both the (E) and (Z) stereoisomers. As a brand name, Sinquan is recognized as one of the original oral formulations of doxepin used across the adult patient group.

Sinquan's Classification: A Tricyclic Antidepressant

Sinquan is classified as a Tricyclic Antidepressant (TCA), positioning it within a foundational class of psychotropic agents primarily acting on the central nervous system. Doxepin functions as a non-selective monoamine reuptake inhibitor, a mechanism that affects the balance of nerve messengers like norepinephrine and serotonin. This dual action profile is clinically recognized as a key differentiator from newer antidepressant classes, supporting its use where anxiety or insomnia are prominent factors.

What is the General Therapeutic Purpose of Doxepin?

The general purpose of Doxepin is to achieve a broad stabilizing effect on the central nervous system, helping to manage mood and anxiety simultaneously. Its primary therapeutic designations are as an antidepressant and an anxiolytic (anti-anxiety agent). The medicine's potent antihistamine properties are directly linked to its strong sedative/hypnotic benefit, supporting its use in patients experiencing difficulty sleeping. Therefore, its overall general purpose is to provide relief by addressing mood instability, anxiety, and related sleep disturbances.

Regulatory References

  1. NIH - Doxepin StatPearls

What side effects are possible with Sinquan?

Possible side effects and safety information

The safety profile of Sinquan (doxepin) is documented by regulatory authorities through specific classifications of adverse reactions, which define both expected effects and serious risks.

Frequency and Classification of Adverse Reactions

Adverse reactions are categorized by their observed frequency in regulatory data. The most common reaction is Drowsiness (Somnolence), which is classified as Very Common (occurring in 1 in 10 patients or more). Side effects classified as Common (occurring in less than 1 in 10 patients but more than 1 in 100) include dry mouth, constipation, dizziness, fatigue, and nausea. These common effects are primarily associated with the Nervous system disorders and Gastrointestinal disorders system-organ classes. Other effects, such as urinary retention, skin rash, or confusion, are classified as Uncommon or Rare.

Serious Safety Information

The official labeling includes documentation regarding certain serious adverse reactions. Among these is the documented risk of suicidal thoughts and behaviors in young adults (le 24 years) during the initial months of therapy and following dosage changes. Other serious events detailed in regulatory documents relate to potential cardiovascular toxicity, including cardiac arrhythmias and severe hypotension, and reports of bone marrow depression.

Safety Considerations for Specific Populations and Conditions

Regulatory documents highlight that older adults may be more susceptible to certain toxic effects, particularly confusion and postural hypotension. The use of Sinquan is explicitly contraindicated in patients with a known tendency toward urinary retention, glaucoma, or pre-existing severe liver disease. Furthermore, it must not be used within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI).

These official safety statements structure the understanding of the medicine's risk profile, detailing which physiological systems are affected and defining the circumstances under which use is prohibited or requires particular caution.

Overdose and Emergency Response

Sinquan Overdose and When to Seek Help

This information is strictly based on official regulatory documentation concerning overdose and emergency management.

Documented Overdose Manifestations

Overdose with this medication can lead to serious and rapidly developing toxicity, primarily affecting the central nervous system (CNS) and the cardiovascular system. Documented manifestations include CNS depression, confusion, agitation, drowsiness, and potentially coma and convulsions (seizures). Cardiovascular effects include severe hypotension (low blood pressure), shock, and dangerous cardiac dysrhythmias (irregular heartbeats), which may be fatal. Other signs may include urinary retention, constipation, dry mouth, blurred vision, and difficulty breathing.

Required Emergency Actions

Immediate medical help must be sought following any suspected overdose. Contacting the local Poison Help line or emergency medical services immediately is required. Because this type of overdose is considered highly toxic and potentially lethal, hospital monitoring and specialized medical care are necessary as soon as possible, even if the individual appears initially asymptomatic. Management procedures may include securing the airway, gastric decontamination (e.g., large volume gastric lavage followed by activated charcoal), and monitoring the electrical activity of the heart (ECG). The severity of the overdose is often clinically assessed by measuring the QRS duration on an ECG.

Population Considerations

In all cases, the risk of intentional overdose necessitates appropriate psychiatric follow-up following recovery.

Therapeutic Uses of Sinquan

What Sinquan Treats: Main Uses and Benefits

The therapeutic relevance of Sinquan (Doxepin) involves several key domains, providing supportive relief for symptoms that interfere with daily functioning. The medication is generally used in managing the symptoms of depression, anxiety, insomnia, and moderate pruritus.

Therapeutic Domains

This medication is applied across domains where additional symptomatic support is needed, such as in the management of major depressive disorder and various forms of anxiety disorders. It also supports patients with chronic insomnia, specifically those with difficulty staying asleep, and is relevant for easing challenging symptoms associated with pruritus (itching). This use may assist with maintaining functional stability when symptoms interfere with routine activities.

“This medication is commonly used to help with symptom clusters that may become intense or disruptive, offering supportive relief for emotional distress and physical discomfort.”

Key Therapeutic Benefits

Sinquan is commonly used to help with emotional tension and low mood, offering support that helps address multiple symptoms simultaneously. Its benefit supports better maintenance of sleep, which may support general well-being during symptomatic phases, and it is relevant for easing symptoms related to skin discomfort. This supports patients during episodes of heightened discomfort and may be part of symptomatic management.


Quick Fact: Relief for Chronic Symptoms The medication is considered relevant in conditions characterized by periods of heightened symptoms, including chronic sleep disturbances and persistent emotional distress.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Sinquan (Doxepin HCl)

This information is based solely on official government regulatory labeling and defines patient eligibility and exclusion criteria.

Absolute Contraindications (Must Not Use)

Condition/Therapy Status
Hypersensitivity to doxepin or dibenzoxepine compounds Contraindicated
Glaucoma (untreated narrow-angle) Contraindicated
Tendency to Urinary Retention or severe retention Contraindicated
Use of Monoamine Oxidase Inhibitors (MAOIs) Contraindicated (Concurrent use or within 14 days)

Conditional Use and Restrictions

Population/Condition Regulatory Status
Pediatric Patients (under 18) Not Established/Not Recommended
Geriatric Patients (65+) Use with Caution; lower doses often required
Pregnancy (especially 3rd Trimester) Not Recommended; safety not established
Breastfeeding Women Not Recommended
Cardiovascular Disease Use with Extreme Caution
Hepatic Impairment Use with Caution; lower starting dose advised

Sinquan is intended for use by adults (18 years and older). Its safety and effectiveness are officially not established for the pediatric population. Certain pre-existing conditions and drug therapies pose a contraindication due to severe risk, requiring strict patient exclusion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sinquan (doxepin) has documented interactions with several drug classes and products, primarily due to its metabolic pathway and central nervous system effects.

Contraindicated Combinations

Monoamine Oxidase Inhibitors (MAOIs) are strictly contraindicated with Sinquan. Concurrent use can lead to serious reactions. A mandatory 14-day washout period is required when switching between Sinquan and an MAOI in either direction.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agents / Classes Resulting Constraint
Metabolic (CYP2D6) Strong CYP2D6 Inhibitors (e.g., Quinidine) Increase in Sinquan and Nordoxepin plasma concentrations; monitoring is required.
Pharmacodynamic CNS Depressants (e.g., Alcohol, Sedatives) Potentiation of central nervous system depressant effects (additive effect).
Antagonistic Guanethidine-related compounds Sinquan may block the antihypertensive action of these drugs.

Food and Timing Considerations

The absorption and exposure of the low-dose tablet formulation for insomnia are significantly affected by food. The drug must not be taken within three hours of a meal to prevent increased systemic exposure (AUC/Cmax). Population-specific notes advise caution in hepatic impairment patients and the elderly due to altered metabolism or increased sensitivity to CNS effects.

Mechanism of Action

How Sinquan (Doxepin) Works at a Biological Level


Modulating Monoamine Neurotransmitter Pathways

Sinquan, a tricyclic compound, acts within domains involving amine-reuptake pumps to regulate signaling processes in the brain. It functions by inhibiting the reuptake of both norepinephrine (NE) and serotonin (5-HT) into the presynaptic neuron, increasing the concentration of these key transmitters in the synaptic cleft. This modification of early molecular steps enhances neurotransmission, resulting in altered concentrations of biogenic amines within the synapse, which influences descending physiological signaling.


Antagonism of Histamine H1 Receptors

The compound engages mechanisms that regulate specific receptor-mediated signaling, notably acting as an antagonist at the central histamine H1 receptors. This blockade suppresses a key signaling sequence for arousal and wakefulness, resulting in characteristic changes to the sleep-wake cycle.


Multi-Receptor Pathway Engagement

The compound also engages non-amine pathways via binding to alpha-1 (alpha1) adrenergic and muscarinic cholinergic receptors. These binding activities modify downstream signaling cascades within systems controlling vascular tone and parasympathetic function. This results in the presentation of associated anticholinergic and anti-adrenergic effects due to specific receptor blockade.

Dosage and Administration Information

Instructions for Sinquan (Doxepin HCl) Administration

Sinquan (doxepin HCl) is an oral medication available in multiple capsule strengths (10 mg to 150 mg) and as an Oral Solution Concentrate (10 mg/mL). Its use follows established procedural and dosing guidelines.

Dosing and Administration Route

Sinquan is administered via the oral route. The standard starting dosage is 75 mg daily, which may be initiated by taking 25 mg three times daily. The target daily dosage often ranges between 75 mg and 150 mg, but the maximum recommended dosage is 300 mg per day.

Dosing Schedule:

  • The total daily dose may be taken in divided doses throughout the day.
  • Alternatively, a single daily dose of up to 150 mg can be taken at bedtime.

Preparation Requirements for Oral Concentrate

If using the Oral Solution Concentrate, specific steps must be followed immediately prior to administration:

  1. Measure the exact prescribed amount of the concentrate using the calibrated dropper provided.
  2. Mix the measured dose with 120 mL (4 oz) of an approved liquid, such as water, whole or skimmed milk, or orange, grapefruit, tomato, prune, or pineapple juice. Do not use other liquids.
  3. Consume the mixture immediately after preparation.

Age-Specific Rules

Sinquan is not recommended for use in pediatric patients under 12 years of age due to limited clinical experience in this population. For elderly patients, prescribers generally administer dosages at the lower end of the recommended range.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sinquan


Evidence for Major Depressive Disorder and Anxiety Disorders

Research into Doxepin's role as a tricyclic compound has been conducted using short-term randomized controlled trials (RCTs) and controlled studies. These studies was studied for its potential as an antidepressant and anxiolytic agent. They evaluated Doxepin's use as a tricyclic compound and explored symptom change related to core manifestations of depression and anxiety using standardized scales.

The findings describe patterns observed in the studies where standardized symptom scores changed over the short observation periods. Studies reported patterns where symptom measurements in the Doxepin groups were observed to vary from placebo outcomes. The results apply only to the populations studied and primarily focus on the use of higher, antidepressant-range doses of the medication (e.g., 75, mg/day or higher). Long-term effects are not fully established for this indication, and the evidence provides limited insight into sustained patterns of change or functional stability.


Evidence for Chronic Insomnia and Sleep Maintenance

The research base for low-dose Doxepin (e.g., le 6, mg) for insomnia is derived from contemporary, controlled, placebo-controlled trials and subsequent systematic reviews. These studies focused specifically on the outcomes reflecting daily functioning or activity level related to sleep. Research examined both objective measures of sleep continuity and patient-reported outcomes describing perceived discomfort from poor sleep.

Contemporary trials documented measurements where objective and subjective sleep measures evolved during the study period. Studies focused on documenting patterns for sleep maintenance. However, there are limited data exploring its effect on the primary difficulty of falling asleep (sleep onset). Additionally, for patients with insomnia who also had a co-existing depression, the low-dose formulation findings were mixed.


Key Limitations and Research Uncertainty

The evidence landscape for Sinquan is characterized by variability. For depression and anxiety, the evidence quality varies across studies because many reflect older research periods and methodologies. Sample sizes were modest in some of these studies. For topical use in moderate pruritus (itching), the follow-up durations were limited, typically restricted to one week or less. The comparative evidence is lacking against other modern, active anti-itch medications. Overall, research contributes to the broader evidence landscape, but evidence highlights what is known — and what is still uncertain regarding functional outcomes beyond the acute treatment phase.

Frequently Asked Questions (FAQ)

Common questions about Sinquan (FAQ)


Q: What's the difference between Sinquan and other similar medicines?

Sinquan is classified as a tricyclic antidepressant (TCA), a foundational class of psychotropic agents. This medicine works by inhibiting the reuptake of two nerve messengers: norepinephrine and serotonin. A notable difference from some newer antidepressants is a strong antihistamine effect, which is noted in its association with sedation and is also utilized in specific low-dose formulations for sleep issues.


Q: Are there any foods or drinks to avoid while using Sinquan?

Official product information describes that alcohol is typically avoided due to the additive effects that increase central nervous system depression. Furthermore, if the low-dose tablet formulation of doxepin for insomnia is being taken, it is not to be taken within three hours of a meal. These requirements are intended to help manage the level of the medicine in the body.


Q: Can Sinquan be used long-term?

Studies examining the use of the antidepressant dose of doxepin were typically short-term, meaning the full effects of chronic use are not fully established in regulatory documents. While research has indicated that antidepressants can help delay the recurrence of depressive episodes, the duration of therapy is a decision that requires consultation with a health professional.


Q: What are the most common reasons people discontinue Sinquan?

Discontinuation of the medication is often related to the most common side effects, such as drowsiness, dizziness, dry mouth, constipation, and fatigue. More seriously, regulatory labeling includes a warning about the emergence of suicidal thoughts and behaviors in young adults. The emergence of severe adverse reactions is a serious event noted in regulatory documents that may lead to the medication being stopped.


Q: What are the signs that Sinquan is starting to work?

Studies indicate that Sinquan addresses key symptoms like anxiety, tension, depression, and sleep disturbances. Official information indicates that for the treatment of depression, it may take between one and three weeks before the full benefit of the medication is noticeable.


Q: What is the general success rate reported in clinical trials for Sinquan?

Regulatory information typically describes the outcomes observed in clinical trials rather than summarizing a single patient-facing 'success rate.' For the low-dose formulation used for insomnia, studies indicated that the incidence of adverse events was comparable to placebo. Research for this use demonstrated maintenance of sleep into the later hours of the night.


Q: How do I know if I'm allergic to Sinquan?

Official information states that its use is contraindicated, meaning it should not be used, if hypersensitivity to the active ingredient, doxepin, is known. Signs of such a reaction can include swelling of the tongue (tongue edema) or the development of hives (urticaria).


Q: How quickly does Sinquan typically start to work?

Based on clinical data, the medication takes time to build up to its full effect in the body. For depression, it may typically take between one and three weeks before the full benefit of the medication is typically noted.


Q: Are there generic versions of Sinquan available?

The active ingredient in the medication, doxepin hydrochloride, is available in generic formulations, including capsules, tablets, and oral solution. These generics are supplied in multiple forms. The original brand name, Sinequan, has been discontinued in the U.S.


Q: Does Sinquan have a risk of causing weight gain?

Official regulatory documents list weight gain as one of the potential side effects that has been reported during the use of doxepin.


Q: Does Sinquan interact with common cold or flu medications?

Interactions are possible with certain over-the-counter cold or flu medications. Caution is described with products containing central nervous system (CNS) depressants or specific serotonergic agents. This carries a risk for additive effects on the central nervous system or, in rare cases, for a condition known as serotonin syndrome.


Q: Does Sinquan cause dependency?

Regulatory information indicates that the active ingredient, doxepin, is generally considered non-addictive. Abuse or dependence regulations have not been required for the medication.


Q: Why do some people use Sinquan for nerve pain?

Research into doxepin’s mechanisms indicates it is a potent blocker of voltage-gated sodium channels. This particular action is thought to contribute to its potential for analgesic effects, which is sometimes explored in a clinical setting for conditions like neuropathic pain. The official designation of the medicine is for mood, anxiety, and sleep disorders.


Q: Is Sinquan safe to use if I have kidney issues?

Doxepin is primarily metabolized in the liver, and the amount excreted by the kidneys is not considered substantial. Caution and close monitoring are described in regulatory documents, particularly in elderly patients who may have reduced kidney function.


Q: What does 'Black Box Warning' mean for a medicine like Sinquan?

The Black Box Warning, officially called a Boxed Warning, is the strongest cautionary statement the FDA can require on a medication’s labeling. For Sinquan, this warning highlights the increased risk of suicidal thoughts and behaviors in young adults (ages 18–24) when taking antidepressants.


Q: Is it necessary to stop taking Sinquan gradually?

Official labeling advises that when discontinuing doxepin hydrochloride capsules, the dosage should be gradually reduced. This procedure helps the body adjust and is a procedure described until the medication is completely stopped.


Q: How long does the effect of a dose of Sinquan last?

Pharmacokinetic data describes how long the drug and its active form remain in the body. The half-life of doxepin is approximately 8 to 24 hours. Its active metabolite, nordoxepin, has a longer half-life, ranging from 28 to 31 hours.


Q: Does Sinquan show up on standard drug tests?

Doxepin is not generally tested for in standard drug screens. However, there have been reports of doxepin potentially causing false-positive results for amphetamines. Due to this possibility, official information suggests informing the testing facility that this medication is being used.


Q: Is it possible to develop a tolerance to Sinquan over time?

In clinical studies of the low-dose formulation used for chronic insomnia, there was no evidence of tolerance reported. Regulatory information does not explicitly summarize data regarding tolerance for the higher doses used for depression.


Q: What if I take too much Sinquan by accident?

Official guidelines state that in the event of an accidental overdose, immediate emergency medical attention is required. Signs of an overdose can include irregular heartbeat, seizures, low blood pressure, and severe drowsiness.


Q: Can Sinquan be taken with pain relievers like ibuprofen?

The combination of Sinquan with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen is noted to require caution. This combination may increase the risk or severity of gastrointestinal bleeding.

How should Sinquan be stored and disposed of?

How to Store and Dispose of Sinquan?

Storage Scope Official Regulatory Requirements
Temperature & Light Store at 20 C to 25 C (68 F to 77 F), which is defined as controlled room temperature. Protect the medication from light, and keep it away from excess heat and moisture.
Container & Handling Keep the capsules in the original container, which should be tightly closed and light-resistant. The product must be kept out of sight and reach of children, preferably in a secured, locked location.
Oral Solution Stability If using the oral solution, it must be mixed with 120 mL of an approved liquid (such as water, milk, or specific juices) and administered immediately after mixing.
Disposal Disposal should follow established regulatory guidance. Patients should use a medicine take-back program when available. If a take-back program is not accessible, unused medication should be disposed of in household trash after mixing with an undesirable substance (e.g., dirt, cat litter) and sealing it in a separate, closed container. Do not flush medication down the toilet unless explicitly instructed by a disposal list.

These storage and disposal requirements ensure the drug's stability and efficacy while emphasizing strict measures to prevent accidental ingestion. The need to protect the product from light and heat, and the specific handling rules for the oral solution, are defined in official labeling to maintain product quality.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinquan found in:

A-Z Index: